Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP

Inclusion Criteria: * Age ≥ 18 years. * Diagnosis of Ph+ or BCR-ABL positive CML-CP within 6 months. * ECOG performance of 0-2. * Adequate end organ function defined as the following: total bilirubin \<1.5x ULN, SGPT \<2.5x ULN, creatinine \<1.5x ULN. * Patients must sign an informed consent form (ICF) indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital Exclusion Criteria: * History of any TKI treatments. * History of Pulmonary arterial hypertension and Pleural effusion * NYHA cardiac class 3-4 heart disease. * Cardiac symptoms - Patients meeting the following criteria are not eligible unless cleared by a cardiologist: * Uncontrolled angina within 12 months. * Diagnosed or suspected congenital long QT syndrome. * Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes). * Prolonged QTc interval on pre-entry electrocardiogram (\>450 msec). * Patients with active uncontrolled psychiatric disorders including: psychosis, major depression, and bipolar disorders. * Women of pregnancy potential must practice an effective method of birth control, unless otherwise instructed, during the course of the study in a manner such that risk of failure is minimized. * Pregnant or breast-feeding women are excluded. * Patients in late chronic phase (i.e. time from diagnosis to treatment \>12 months), accelerated phase (except as noted in inclusion criteria 2) or blast phase are excluded.